Rovamycin Forte Tablet

Spiramycine
3Million IU
Abbott India Ltd.
Pack size
Dispensing mode
Source
Agent
Retail Price 79.11 NPR

Indications

Rovamycin Forte Tablet is used for: Susceptible infections, Cryptosporidiosis, Toxoplasmosis, Protozoal infections

Adult Dose

Oral Toxoplasmosis; Protozoal infections; Cryptosporidiosis; Susceptible infections Adult: 6-9 million units/day in 2-3 divided doses, increased to 15 million units/day, given in divided doses for severe infections.

Child Dose

Oral Child and Neonates: Chemoprophylaxis of congenital toxoplasmosis: 50 mg/kg bid.

Renal Dose

Administration

May be taken with or without food.

Contra Indications

Hypersensitivity.

Precautions

Hepatic impairment; pregnancy and lactation. Monitor liver function. History of arrhythmias or predisposition to QT interval prolongation.

Pregnancy-Lactation

Interactions

Decreases carbidopa absorption and levodopa concentrations. Increased risk of ventricular arrhythmias when used with astemizole, cisapride and terfenadine. Risk of acute dystonia when used with fluphenazine.

Adverse Effects

Side effects of Spiramycine : Nausea, vomiting, abdominal pain, diarrhoea; urticaria, pruritus, macular rashes. Transient paraesthesia may occur. Potentially Fatal: Pseudomembranous colitis; anaphylaxis; neuromuscular blockade; ventricular arrhythmias, prolongation of QT interval.

Mechanism of Action

Spiramycin is a macrolide antibacterial that inhibits protein synthesis by irreversibly binding to the 50S subunit of the ribosomal subunit thus blocking the transpeptidation or translocation reactions of susceptible organisms resulting in stunted cell growth

Note

Rovamycin Forte 3Million IU Tablet manufactured by Abbott India Ltd.. Its generic name is Spiramycine. Rovamycin Forte is availble in Nepal. Farmaco Nepal drug index information on Rovamycin Forte Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Spiramycine :